Marina Biotech Describes Integrated Technology Platform for the Development of RNAi-, microRNA- and Antisense-based Therapeutics
Product News Feb 15, 2011
Marina Biotech, Inc. has presented their integrated technology platform for the discovery of multiple oligonucleotide based therapeutics including RNAi-, microRNA- and antisense-based drugs at the BIO CEO and Investor Conference held in New York City. J. Michael French, President and CEO of Marina Biotech, Inc. explained the strategy behind Marina Biotech's acquisition of key intellectual property and technologies over the past year which has positioned it to provide multiple RNA-based therapeutic alternatives to pharma's non-druggable target needs.
With the Debiopharm partnership fully funding the development of the Company's bladder cancer program using the Company's proprietary DiLA2 delivery technology for local administration combined with licensee ProNAi funding a Phase 1 clinical trial using the Company's proprietary Smarticles® delivery technology for systemic administration; the Company is focusing its financial resources on the Phase 1b/2a clinical trial of CEQ508 in Familial Adenomatous Polyposis (FAP) as well as development of its Conformationally Restricted Nucleotide technology (CRN) for the development of single-stranded oligonucleotide therapies.
"We find ourselves in an enviable position where others are funding the development and human testing of our proprietary technologies allowing us to focus resources on our clinical program in FAP and CRN technology," stated J. Michael French, President and CEO of Marina Biotech, Inc.
French continued, "We believe our recently announced Debiopharm collaboration, ProNAi's advancement into human clinical testing of its oncology drug candidate with our delivery technology, and our internal clinical program in FAP validates our ability to deliver nucleic acid-based therapeutics via local, systemic and oral administration. We plan to focus our research efforts in expanding our opportunities in systemic administration by applying our CRN technology to the development of single-stranded oligonucleotide therapeutics. We believe this approach will provide us with additional and potentially greater opportunities for pharma collaborations as well as reducing our annual operating expenses."